| Objective To study the efficacy and safety of carvedilol in cardiac function improvement for the patient of congestive heart failure. Methods Eighty-six patients. They was male 49 and female 8.The NYHA class was from II to IV, the ejection of them was 0.45. On a basic medical therapy including digitalis diuretics and ACE-I, carvedilol were titrated from low dose(3.125mg Bid) to target dose. The target does was 50mg every day. They were divided randomly into carvedilol group and control group for 3.5 to 6 months follow-up period. The data of left ventricular function and volume were measured by radionuclide ventriculography. Results After 3.5 to 6 months, therapy carvedilol group symptom scores and NYHA class improved, as reflected by the increased left ventricular ejection by (23.31 6.0) %to (42.53 4.6) %, P=0.0012, both the decreased left ventricular end-systolic and the decreased left ventricularend-diastolic volume. ESV(146.31 19.14)ml vs (79.56 14.27)ml P=0.0026, EDV(189.97 29.9)ml vs (137.92 19.14)ml P=0.0037. In carvedilol group twenty-three patients (60.5%) were tolerant target does (25mg Bid). All the patients haven't special side effect. The common symptom is dizziness. No significant change of liver, renal function, blood sugar, blood lipid, electrolyte and blood routine test were occurred in carvedilol group. Conclusion This study indicates that based on the standard medical therapy, carvedilol can improve left ventricular performance, reverse LV remodeling in patients with mild and moderate chronic heart failure. Carvedilol is safe and efficacious for therapy of chronic heart failure. |
